Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Abstract Development and Phase 3 testing of the most advanced malaria vaccine, RTS,
S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of …

Background The planning and assessment of malaria interventions is complicated due to
fluctuations in the burden of malaria over time. Recently, it has been reported that the …

Plasmodium falciparum malaria is a major global health problem, responsible for up to 1
million deaths each year. Major efforts have been made to develop an effective vaccine …

Since the recent call for a shift from malaria control to eradication, the role of asexual blood
stage vaccines for falciparum malaria, which are not expected to prevent infection, has …

There is no malaria vaccine currently available, and the most advanced candidate has
recently reported a modest 30% efficacy against clinical malaria. Although many efforts have …

Despite the many efforts of researchers around the world, there is currently no effective
vaccine for malaria. Numerous studies have been developed to find vaccine antigens that …

Background In the advent of increasing international collaborative research involving
participants drawn from populations with diverse cultural backgrounds, community …

In the absence of an effective vaccine against malaria suitable for widespread deployment,
the control of this lethal infectious disease relies heavily on antimalarial chemotherapies …

The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand
that mediates erythrocyte invasion and is considered an important malaria vaccine …